• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Entrada Therapeutics, Inc. - Common Stock (NQ:TRDA)

5.970 -0.400 (-6.28%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 269,066
Open 6.340
Bid (Size) 5.800 (100)
Ask (Size) 6.500 (400)
Prev. Close 6.370
Today's Range 5.950 - 6.500
52wk Range 4.930 - 16.45
Shares Outstanding 33,197,018
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA
June 02, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study
June 02, 2026
From Entrada Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-40.6%
-40.6%
1 Month
-14.7%
-14.7%
3 Month
-54.8%
-54.8%
6 Month
-43.6%
-43.6%
1 Year
-26.4%
-26.4%

More News

Read More
News headline image
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 01, 2026
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA
May 26, 2026
From Pomerantz LLP
Via GlobeNewswire
Entrada Therapeutics (NASDAQ:TRDA) Plunges Nearly 48% as Early-Stage DMD Clinical Data Disappoints on Drug Exposure ↗
May 07, 2026
Via Chartmill
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA
May 19, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
TRDA Investors Have Opportunity to Join Entrada Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
May 17, 2026
From Schall Law
Via GlobeNewswire
News headline image
Entrada Therapeutics DMD Trial Shows Early Functional Gains, Clean Safety Profile ↗
May 09, 2026
Via MarketBeat
Which stocks are experiencing notable movement on Thursday? ↗
May 07, 2026
Via Chartmill
Top stock movements in today's session. ↗
May 07, 2026
Via Chartmill
There are notable gap-ups and gap-downs in today's session. ↗
May 07, 2026
Via Chartmill
Which stocks are moving before the opening bell on Thursday? ↗
May 07, 2026
Via Chartmill
News headline image
Entrada Therapeutics Reports First Quarter 2026 Financial Results
May 07, 2026
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study
May 07, 2026
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026
May 06, 2026
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit ↗
March 18, 2026
Via The Motley Fool
News headline image
Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit ↗
March 18, 2026
Via The Motley Fool
News headline image
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 02, 2026
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
February 26, 2026
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study
February 17, 2026
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics to Present at Upcoming Investor Conferences
February 04, 2026
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases
January 08, 2026
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 17, 2025
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 04, 2025
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
What One Fund's Sale of Centessa Stock Signals About the Fast-Rising Biotech Company ↗
November 29, 2025
Via The Motley Fool
Topics Regulatory Compliance

Frequently Asked Questions

Is Entrada Therapeutics, Inc. - Common Stock publicly traded?
Yes, Entrada Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Entrada Therapeutics, Inc. - Common Stock trade on?
Entrada Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Entrada Therapeutics, Inc. - Common Stock?
The ticker symbol for Entrada Therapeutics, Inc. - Common Stock is TRDA on the Nasdaq Stock Market
What is the current price of Entrada Therapeutics, Inc. - Common Stock?
The current price of Entrada Therapeutics, Inc. - Common Stock is 5.970
When was Entrada Therapeutics, Inc. - Common Stock last traded?
The last trade of Entrada Therapeutics, Inc. - Common Stock was at 06/10/26 04:00 PM ET
What is the market capitalization of Entrada Therapeutics, Inc. - Common Stock?
The market capitalization of Entrada Therapeutics, Inc. - Common Stock is 198.19M
How many shares of Entrada Therapeutics, Inc. - Common Stock are outstanding?
Entrada Therapeutics, Inc. - Common Stock has 198M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap